Upcoming Conferences for Aardvark Therapeutics
In an exciting move, Aardvark Therapeutics, Inc. (NASDAQ: AARD), a cutting-edge biopharmaceutical firm, has announced it will present at several key investor conferences this September. With a particular emphasis on its innovative small-molecule therapeutics aimed at treating metabolic disorders, Aardvark is positioned to share its latest advancements.
Conference Schedule
The company will take part in the following prestigious events:
Cantor Fitzgerald Global Healthcare Conference
Date & Time: September 3 at 11:30 a.m. ET
Location: New York
Morgan Stanley Annual Global Healthcare Conference
Date & Time: September 8 at 7:00 a.m. ET
Location: New York
H.C. Wainwright Annual Global Investment Conference
Date & Time: September 10 at 10:30 a.m. ET
Location: New York
Live Presentation Access
For those interested, Aardvark will provide live webcasts of each presentation, available through their official website. These webcasts will be easily accessible in the investors' section. Additionally, recorded versions will remain available for approximately one month following these conferences, ensuring broader access to their insights and developments.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, a pioneering clinical-stage biopharmaceutical company, specializes in the development of unique, small-molecule therapeutics. These are specifically designed to target innate homeostatic pathways, particularly in areas related to metabolic diseases. Aardvark's innovative approach focuses on a deeper understanding of hunger versus appetite, which can lead to groundbreaking therapies for conditions such as Prader-Willi Syndrome (PWS) and other metabolic disorders.
The flagship compound, ARD-101, is currently in Phase 3 clinical trials, designed to treat hyperphagia connected to PWS, a rare condition that causes individuals to experience constant hunger. Aardvark is also exploring the therapeutic potential of ARD-101 for hypothalamic obesity.
In addition, Aardvark is developing ARD-201, a combination therapy that integrates ARD-101 with a DPP-4 inhibitor. This is aimed at overcoming current limitations seen in marketed GLP-1 therapies for obesity and related disorders. The company’s commitment to innovation ultimately seeks to improve the quality of life for those affected by such conditions.
Contact Information
For further inquiries, you can reach out to Carolyn Hawley at Inizio Evoke Communications. She can be contacted via phone at (619) 849-5382 or via email at Carolyn.hawley@inizioevoke.com.
Frequently Asked Questions
What does Aardvark Therapeutics focus on?
Aardvark focuses on developing small-molecule therapeutics to treat metabolic diseases and activate innate homeostatic pathways.
When are Aardvark's presentations scheduled?
Aardvark has presentations lined up for September 3, 8, and 10 at major healthcare conferences.
How can I access the presentations?
Live webcasts of the presentations will be available on Aardvark's website, along with archived recordings for a month afterward.
What is ARD-101?
ARD-101 is Aardvark's lead compound currently in Phase 3 clinical development for treating hyperphagia related to Prader-Willi Syndrome.
Who can I contact for more information?
You can contact Carolyn Hawley at Inizio Evoke Communications for any inquiries regarding Aardvark Therapeutics.
